SQZ Biotechnologies (SQZB)
(Delayed Data from OTC)
$0.04 USD
0.00 (0.00%)
Updated Jun 26, 2024 11:04 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for SQZ Biotechnologies Company falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 21 | 27 | 21 | 20 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 21 | 27 | 21 | 20 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 102 | 96 | 72 | 54 |
Income After Depreciation & Amortization | 0 | -81 | -69 | -51 | -34 |
Non-Operating Income | NA | 1 | 0 | 1 | 2 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -79 | -69 | -51 | -32 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -79 | -69 | -51 | -32 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -79 | -69 | -51 | -32 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -69 | -58 | -40 | -31 |
Depreciation & Amortization (Cash Flow) | NA | 12 | 11 | 11 | 3 |
Income After Depreciation & Amortization | 0 | -81 | -69 | -51 | -34 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 28.81 | 27.58 | 5.40 | NA |
Diluted EPS Before Non-Recurring Items | NA | -2.76 | -2.49 | -9.35 | NA |
Diluted Net EPS (GAAP) | NA | -2.76 | -2.49 | -9.35 | NA |
Fiscal Year end for SQZ Biotechnologies Company falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | 0.00 | 0.18 | 0.00 |
Cost Of Goods | NA | NA | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | NA | 0.00 | 0.18 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 23.80 | 17.29 | 18.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | -23.80 | -17.11 | -18.26 |
Non-Operating Income | NA | NA | 0.16 | 0.34 | 0.57 |
Interest Expense | NA | NA | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | NA | -23.64 | -16.77 | -17.69 |
Income Taxes | NA | NA | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | -23.64 | -16.77 | -17.69 |
Extras & Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | -23.64 | -16.77 | -17.69 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 29.49 | 29.49 | 29.49 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.54 | -0.57 | -0.60 |
Diluted Net EPS (GAAP) | NA | NA | -0.80 | -0.57 | -0.60 |